📣 VC round data is live. Check it out!
- Public Comps
- Pyridam Farma
Pyridam Farma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pyridam Farma and similar public comparables like Hamlet BioPharma, Mersana Therapeutics, Satellos Bioscience, Orthocell and more.
Pyridam Farma Overview
About Pyridam Farma
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. The company derives maximum revenue from Pharmaceutical Products and Toll Manufacturing Services. The company's products include consumer health, Derma, prescription, and biomedilab.
Founded
1976
HQ

Employees
1.4K
Website
Financials (FY)
EV
$410M
Valuation Multiples
Start free trialPyridam Farma Financials
Pyridam Farma reported last fiscal year revenue of $155M and negative EBITDA of ($6M).
In the same fiscal year, Pyridam Farma generated $33M in gross profit, ($6M) in EBITDA losses, and had net loss of ($21M).
Pyridam Farma P&L
In the most recent fiscal year, Pyridam Farma reported revenue of $155M and EBITDA of ($6M).
Pyridam Farma is unprofitable as of last fiscal year, with gross margin of 21%, EBITDA margin of (4%), and net margin of (14%).
Financial data powered by Morningstar, Inc.
Pyridam Farma Stock Performance
Pyridam Farma has current market cap of $145M, and enterprise value of $410M.
Market Cap Evolution
Pyridam Farma's stock price is $0.01.
Pyridam Farma share price decreased by 1.1% in the last 30 days, and by 8.2% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $410M | $145M | -1.1% | -1.1% | -28.8% | -8.2% | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPyridam Farma Valuation Multiples
Pyridam Farma trades at 2.7x EV/Revenue multiple, and (63.1x) EV/EBITDA.
Pyridam Farma Financial Valuation Multiples
As of June 3, 2026, Pyridam Farma has market cap of $145M and EV of $410M.
Pyridam Farma has a P/E ratio of (6.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pyridam Farma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Pyridam Farma Margins & Growth Rates
In the most recent fiscal year, Pyridam Farma reported gross margin of 21%, EBITDA margin of (4%), and net margin of (14%).
Pyridam Farma Margins
Pyridam Farma Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Pyridam Farma Operational KPIs
Pyridam Farma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Pyridam Farma Competitors
Pyridam Farma competitors include Hamlet BioPharma, Mersana Therapeutics, Satellos Bioscience, Orthocell, Molecular Partners, AN2 Therapeutics, Kotra Industries, Oramed Pharmaceuticals, Agenus and Vytrus Biotech.
Most Pyridam Farma public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | (30.0x) | - | |||
| - | - | - | - | |||
| - | - | (2.9x) | - | |||
| 19.0x | 12.8x | (21.9x) | (14.0x) | |||
| - | 16.0x | (0.7x) | (0.7x) | |||
| - | - | (1.6x) | - | |||
| 2.3x | 2.5x | 8.3x | 9.3x | |||
| 41.2x | 41.2x | 1.1x | - | |||
This data is available for Pro users. Sign up to see all Pyridam Farma competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pyridam Farma
| When was Pyridam Farma founded? | Pyridam Farma was founded in 1976. |
| Where is Pyridam Farma headquartered? | Pyridam Farma is headquartered in Indonesia. |
| How many employees does Pyridam Farma have? | As of today, Pyridam Farma has over 1K employees. |
| Is Pyridam Farma publicly listed? | Yes, Pyridam Farma is a public company listed on Indonesia Stock Exchange. |
| What is the stock symbol of Pyridam Farma? | Pyridam Farma trades under PYFA ticker. |
| When did Pyridam Farma go public? | Pyridam Farma went public in 2001. |
| Who are competitors of Pyridam Farma? | Pyridam Farma main competitors include Hamlet BioPharma, Mersana Therapeutics, Satellos Bioscience, Orthocell, Molecular Partners, AN2 Therapeutics, Kotra Industries, Oramed Pharmaceuticals, Agenus, Vytrus Biotech. |
| What is the current market cap of Pyridam Farma? | Pyridam Farma's current market cap is $145M. |
| What is the current revenue of Pyridam Farma? | Pyridam Farma's last fiscal year revenue is $155M. |
| What is the current EV/Revenue multiple of Pyridam Farma? | Current revenue multiple of Pyridam Farma is 2.7x. |
| Is Pyridam Farma profitable? | No, Pyridam Farma is not profitable. |
| How many companies Pyridam Farma has acquired to date? | Pyridam Farma hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Pyridam Farma has invested to date? | Pyridam Farma hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Pyridam Farma
Lists including Pyridam Farma
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.